We are live on ! Find out more
OSTX icon

OS Therapies

6 hedge funds and large institutions have $624K invested in OS Therapies in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.08% less ownership

Funds ownership: 0.77% → 0.69% (-0.08%)

16% less capital inflows, than outflows

Capital inflows: $191K | Capital outflows: $228K

25% less funds holding

Funds holding: 8 → 6 (-2)

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
6
Holders Change
-2
Holders Change %
-25%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

OSTX Hedge Fund Activity: Q4 2024 in Review

6 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in OS Therapies (OSTX) for Q4 2024, worth a combined $624K — up 39% from $449K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of OSTX and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was CM Management, adding an estimated $176K. The largest seller was Millennium Management, cutting an estimated $89.7K.

  • 6 institutional investors held OS Therapies (OSTX) as of Q4 2024, down from 8 in Q3 2024.
  • Funds reported $624K of OS Therapies stock for Q4 2024, up 39% quarter-over-quarter.
  • 2 funds opened new OS Therapies positions in Q4 2024 and 4 closed out, a net change of -2 holders.
  • The largest OS Therapies buyer in Q4 2024 was CM Management, an estimated $176K added.
  • The largest OS Therapies seller in Q4 2024 was Millennium Management, an estimated $89.7K sold.

Based on aggregated 13F filings for Q4 2024.